Clinical Researches
Promoter methylation regulated oncostatin M receptor expression is associated with poor prognosis of patients with gastric cancer
Wei Haiyan, Dou Tingting, Wang Guozhou, Liu Xunbi, Li Xia, Fang Xiaochang, Zheng Xinyu, Chen Tianliang, Li Xuanfei
Published 2021-09-08
Cite as Chin J Exp Surg, 2021, 38(9): 1772-1774. DOI: 10.3760/cma.j.cn421213-202011124-01425
Abstract
ObjectiveTo investigate the expression and significance of promoter methylation regulated oncostatin M receptor (OSMR) in gastric cancer.
MethodsChi-square test and pearson correlation analysis were respectivelty used to explore the expression levels and regulation relationship of OSMR mRNA and its promoter methylation in gastric cancer in UCSC Xena database. Immunohistochemistry was used to detect the expression of OSMR protein in 80 cases of gastric cancer tissues. Furthermore, we analyzed the relationship between OSMR protein expression and the clinical features and survival of 80 patients with gastric cancer.
ResultsBioinformatics analysis through UCSC Xena database suggested that OSMR mRNA expression was elevated (14.752±7.593 vs. 8.098±3.457, t=-8.938, P<0.01), whereas the promoter methylation level of OSMR was reduced (0.195±0.104 vs. 0.463±0.187,t=9.372, P<0.01) in gastric cancer. Furthermore, correlation analysis revealed that OSMR mRNA level was negatively related with its promoter methylation (R=-0.562, t=-14.517, P<0.01) in gastric cancer. Kaplan-Meier survival analysis suggested that OSMR protein expression was significantly associated with poor 5-year overall survival [hazard ratio (HR)=1.535, 95% confidence interval (CI): 1.214-1.873, P<0.01]. In addition, the high expression of OSMR protein was closely related to tumor differentiation degree (χ2=9.389, P<0.01), TNM stage (χ2=8.166, P<0.01) and lymphatic metastasis (χ2=4.233, P<0.05).
ConclusionPromoter methylation regulated OSMR expression is increased and asscciated with poor prognosis in gastric cancer.
Key words:
Promoter methylation; Gastric cancer; Prognosis
Contributor Information
Wei Haiyan
Department of Public Health, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi 435000, China
Dou Tingting
Department of Gastrointestinal Surgery, Zhongnan Hospital, Clinical Medical Research Center of Peritoneal Cancer of Wuhan, Clinical Cancer Study Center of Hubei Provence, Key Laboratory of Tumor Biological Behavior of Hubei Provence, Wuhan 430071, China
Wang Guozhou
Department of Breast Cancer Surgery, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi 435000, China
Liu Xunbi
Department of Breast Cancer Surgery, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi 435000, China
Li Xia
Department of Breast Cancer Surgery, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi 435000, China
Fang Xiaochang
Department of Gastrointestinal Surgery, Zhongnan Hospital, Clinical Medical Research Center of Peritoneal Cancer of Wuhan, Clinical Cancer Study Center of Hubei Provence, Key Laboratory of Tumor Biological Behavior of Hubei Provence, Wuhan 430071, China
Zheng Xinyu
Department of Gastrointestinal Surgery, Zhongnan Hospital, Clinical Medical Research Center of Peritoneal Cancer of Wuhan, Clinical Cancer Study Center of Hubei Provence, Key Laboratory of Tumor Biological Behavior of Hubei Provence, Wuhan 430071, China
Chen Tianliang
Department of Gastrointestinal Surgery, Zhongnan Hospital, Clinical Medical Research Center of Peritoneal Cancer of Wuhan, Clinical Cancer Study Center of Hubei Provence, Key Laboratory of Tumor Biological Behavior of Hubei Provence, Wuhan 430071, China
Li Xuanfei
Department of Gastrointestinal Surgery, Zhongnan Hospital, Clinical Medical Research Center of Peritoneal Cancer of Wuhan, Clinical Cancer Study Center of Hubei Provence, Key Laboratory of Tumor Biological Behavior of Hubei Provence, Wuhan 430071, China
